Munich, Germany

Margret Schottelius

USPTO Granted Patents = 7 


 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2009-2025

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: **Innovations by Margret Schottelius in Medical Imaging and Therapy**

Introduction

Margret Schottelius is a notable inventor based in Munich, Germany, recognized for her significant contributions to the field of medical imaging and therapeutic agents. With a portfolio comprising six patents, her work primarily focuses on innovative solutions targeting diseases involving the chemokine receptor 4 (CXCR4).

Latest Patents

Among her latest patents are groundbreaking developments related to CXCR4-targeted diagnostic and therapeutic agents. The first patent details imaging and endoradiotherapy agents designed to effectively bind or inhibit both human (hCXCR4) and mouse (mCXCR4) receptors. These compounds are equipped with moieties suitable for labeling, which enhances their applicability in medical imaging and cancer treatment. The second patent further emphasizes the utility of these compounds for therapeutic and diagnostic purposes in cancer, reinforcing the potential of CXCR4 as a target for innovative cancer therapies.

Career Highlights

Margret Schottelius has had a distinguished career, working with prestigious organizations such as Technische Universität München and Mallinckrodt, Inc. Her academic and professional affiliations have allowed her to push the boundaries of research and innovation in her field.

Collaborations

Throughout her career, Margret has collaborated with esteemed colleagues, including Hans-Jürgen Wester and Theresa Osl. These collaborations have fostered an environment of innovation and contributed to the success of her projects, particularly in the intersection of medical research and patenting.

Conclusion

In conclusion, Margret Schottelius stands out as a pioneering inventor in the realm of medical therapeutics and diagnostics. Her advancements in CXCR4-targeted agents mark significant progress in cancer treatment options, showcasing the vital role of innovation in improving health outcomes. Her contributions continue to influence the field, and her patents lay a foundation for further research and development opportunities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…